Correct Answer: A. DDAVP supplementation for lifelong
This patient has central diabetes insipidus (CDI) secondary to total hypophysectomy. The clinical triad is pathognomonic: polyuria, hypernatremia (Na+ 155 mEq/L; normal 135–145), and dilute urine (osmolarity 200 mOsm/L; normal >600 mOsm/L). Total hypophysectomy destroys the posterior pituitary, eliminating ADH (vasopressin) production. Without ADH, the kidneys cannot reabsorb free water in the collecting duct, causing massive polyuria and secondary hypernatremia.
Central DI is a permanent, lifelong condition when the posterior pituitary is surgically ablated. The only definitive management is lifelong DDAVP (desmopressin) supplementation—a synthetic ADH analogue that replaces the missing hormone. DDAVP can be given intranasally, orally, or parenterally. The dose is titrated to normalize serum sodium and urine output. Unlike nephrogenic DI (where DDAVP is ineffective), CDI responds dramatically to DDAVP. In Indian practice, intranasal DDAVP spray (10–20 µg twice daily) or oral tablets (0.1–0.2 mg three times daily) are standard. Lifelong replacement is mandatory because the posterior pituitary does not regenerate after total hypophysectomy. This is consistent with Harrison's endocrinology principles and Indian DOC guidelines for pituitary disorders.
Why the other options are wrong
B. Thiazides for 2 weeks — Thiazides are used in nephrogenic DI (where kidneys are insensitive to ADH), not central DI. Thiazides cause mild volume depletion and enhance proximal tubular reabsorption of sodium and water, reducing polyuria in nephrogenic DI only. In central DI, thiazides are ineffective because the problem is ADH deficiency, not renal insensitivity. This is a classic NBE trap confusing the two types of DI. C. Upsetting of receptors so no treatment is required — This option is nonsensical and appears designed to trap students unfamiliar with DI pathophysiology. Total hypophysectomy causes irreversible destruction of ADH-secreting neurons in the posterior pituitary. There is no 'receptor upset' that self-resolves. Without ADH replacement, the patient will remain polyuric and hypernatremic indefinitely, risking seizures, coma, and death. No spontaneous recovery occurs. D. DDAVP for 2 weeks and then discontinue — This reflects a fundamental misunderstanding of central DI pathophysiology. After total hypophysectomy, the posterior pituitary is permanently destroyed—it does not regenerate. DDAVP must be continued lifelong. Discontinuing after 2 weeks would result in recurrence of polyuria, hypernatremia, and life-threatening dehydration. This trap assumes students think the pituitary can recover, which it cannot.
High-Yield Facts
- Central DI post-hypophysectomy = permanent ADH deficiency requiring lifelong DDAVP replacement.
- Diagnostic triad of CDI: polyuria + hypernatremia (Na+ >150 mEq/L) + dilute urine (osmolarity <300 mOsm/L).
- DDAVP is the DOC for central DI; intranasal spray (10–20 µg BD) or oral tablets (0.1–0.2 mg TDS) are standard Indian formulations.
- Nephrogenic DI (not this case) uses thiazides or NSAIDs; central DI does not respond to thiazides.
- Posterior pituitary does not regenerate after surgical ablation; therefore, DDAVP replacement is permanent, not temporary.
Mnemonics
CDI vs NDI: DDAVP Response Central DI = Cures with DDAVP (responds well). Nephrogenic DI = No response to DDAVP (use thiazides instead). Use when differentiating DI types on clinical exams. Post-Hypophysectomy DI: LIFELONG Rule Loss of pituitary = Lifelong DDAVP. Irreversible damage = Infinite replacement. Forever hormone = Forever therapy. Prevents the trap of thinking temporary DDAVP is sufficient.
NBE Trap
NBE pairs 'DI' with 'thiazides' to trap students who confuse central DI (DDAVP-responsive) with nephrogenic DI (thiazide-responsive). The 'discontinue after 2 weeks' option exploits the misconception that the pituitary can regenerate after surgical ablation—it cannot.
Clinical Pearl
In Indian tertiary care, post-hypophysectomy patients often present weeks later with severe polyuria and hypernatremia when DDAVP is not prescribed at discharge. Bedside pearl: any patient with polyuria + hypernatremia + dilute urine after pituitary surgery needs immediate DDAVP; delayed recognition risks seizures and ICU admission. Lifelong follow-up with endocrinology is mandatory to titrate DDAVP dose and monitor serum sodium.
_Reference: Harrison Ch. 375 (Disorders of the Pituitary); KD Tripathi Ch. 31 (Anterior and Posterior Pituitary Hormones); Robbins Ch. 24 (Endocrine System)_